- Home
- A-Z Publications
- Current Pharmaceutical Design
- Previous Issues
- Volume 16, Issue 33, 2010
Current Pharmaceutical Design - Volume 16, Issue 33, 2010
Volume 16, Issue 33, 2010
-
-
Current Developments for the Diagnosis and Treatment of Irritable Bowel Syndrome
Authors: Oliver Grundmann, Saunjoo L. Yoon and Baharak MoshireeCurrent treatment options for the chronic gastrointestinal disorder irritable bowel syndrome (IBS) have long been limited to symptomatic treatments due to lack of pathophysiologic understanding of the syndrome. Within the past 10 years, however, a number of new pharmacological targets have been identified that may aid in the treatment of irritable bowel syndrome. Although only a limited number of new drug enti Read More
-
-
-
Implications of Melatonin Therapy in Irritable Bowel Syndrome: A Systematic Review
Authors: Shilan Mozaffari, Roja Rahimi and Mohammad AbdollahiIrritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal (GI) disorder associated with abdominal pain and change in bowel habits that its etiology is not known yet. In the recent years, melatonin has been proposed as a possible candidate. In the present work, all clinical or non-clinical data about effects of melatonin in GI tract and IBS obtained from literature without time limit up to August 2010 h Read More
-
-
-
Targeting IL-23 and Th17-Cytokines in Inflammatory Bowel Diseases
Over the last 15 years, the use of various biological therapies has largely improved the way we manage patients with Inflammatory Bowel Diseases (IBDs). Blockade of cytokine synthesis and/or activity is at the forefront of this new era with the success of inhibitors of tumor necrosis factor (TNF)-α. These therapies are however not effective in all IBD patients and efficacy may wane. Moreover, patients treated with anti-TNF-α antib Read More
-
-
-
Phosphodiesterase 4 Inhibitors in Inflammatory Bowel Disease: A Comprehensive Review
Authors: Pooneh Salari-Sharif and Mohammad AbdollahiInflammatory bowel disease (IBD) is known as a chronic inflammation of gastrointestinal tract that its pathogenesis still is not completely understood. Several drug categories are used for management of IBD but there is no exact cure for the disease, however biological drugs targeting the inflammation of gut are on the center of attention. In investigating the anti-inflammatory drugs, phosphodiesterase inhibitors were f Read More
-
-
-
Current Therapeutic Approaches in Inflammatory Bowel Disease
Authors: Amir Ali Sohrabpour, Reza Malekzadeh and Ali KeshavarzianInflammatory bowel disease (IBD) is a chronic, relapsing, inflammatory disorder of the gastrointestinal tract and is broadly classified into Crohn's disease (CD) and ulcerative colitis (UC). In the last decade, our understanding of the etiology and pathogenesis of this group of disorders has been improved. More specifically, recent development of biologics and use of immunomodulator agents in IBD have made it possible to robus Read More
-
-
-
Efficacy and Tolerability of Immunoregulators and Antibiotics in Fistulizing Crohn's Disease: A Systematic Review and Meta-analysis of Placebo-controlled Trials
Authors: Shekoufeh Nikfar, Hadi Mirfazaelian and Mohammad AbdollahiObjective: This meta-analysis of randomized controlled trials was conducted to evaluate the efficacy and tolerability of two drug groups (immunoregulators and antibiotics) in the treatment of fistula in Crohn's disease (CD). Methods: PubMed, Embase, Scopus, Google Scholar, and Web of Science were searched for clinical trial studies investigated the effects of immunoregulators and antibiotics in the treatment of fistuliz Read More
-
-
-
Editorial [Hot topic:Sealing the Envelope-the HIV-1 Envelope Glycoproteins as Targets for Therapeutics and Vaccines (Executive Editors: Rogier W. Sanders, Ben Berkhout)]
Authors: Rogier W. Sanders and Ben BerkhoutHIV-1 is an enveloped virus that derives its lipid envelope from the virus producing cell. The envelope glycoprotein complex (Env) mediates viral attachment to and entry in susceptible target cells and is therefore an attractive target for therapeutic intervention. The T20 peptide (Fuzeon, enfuvirtide), targeting the Env fusion machinery, was approved for clinical use in 2003 and served as salvage therapy for many HIV-1 inf Read More
-
-
-
HIV-1 (co)Receptors: Implications for Vaccine and Therapy Design
Authors: Georgios Pollakis and William A PaxtonThe ultimate aim of therapy or vaccine design against HIV is to eliminate ongoing virus replication or prevent HIV infection. The task at hand is daunting given the wide array of HIV variants circulating and the immense degree of variation found within the virus, especially in the envelope glycoprotein. HIV utilizes the CD4 receptor and a range of 7 transmembrane chemokine coreceptors for cell entry, specifically CCR5 and Read More
-
-
-
Inhibition of HIV-1 by Fusion Inhibitors
Authors: Dirk Eggink, Ben Berkhout and Rogier W. SandersThe envelope glycoprotein complex (Env) is responsible for entry of the human immunodeficiency virus type 1 (HIV-1) into cells by mediating attachment to target cells and subsequent membrane fusion. Env consists of three gp120 subunits that mediate receptor and co-receptor attachment and three gp41 subunits responsible for membrane fusion. Several steps of the entry process can serve as drug targets. Re Read More
-
-
-
Antibody Epitope Exposure and Neutralization of HIV-1
More LessFormulating an effective HIV vaccine remains a formidable challenge despite nearly 3 decades of intense research since the virus was first isolated. One of the obstacles that need to be surmounted is the design of a preparation that elicits a potent and broadly neutralizing antibody (nAb) response, i.e. antibodies with the capacity to block infectivity of the genetically diverse pool of HIV strains that circulate globally. The pri Read More
-
-
-
Structure-based Vaccine Design in HIV: Blind Men and the Elephant?
Authors: Robert Pejchal and Ian A. WilsonTraditional vaccine approaches have failed for HIV and novel strategies are now being sought to develop immunogens designed to elicit specific activity against known broad neutralization epitopes. Structure-based vaccine design has great potential but, so far, remains a largely unproven concept. Further structural information for the envelope (Env) glycoproteins, gp120 and gp41, would be extremely beneficial, particularl Read More
-
-
-
Therapeutic Antibodies in HIV Treatment - Classical Approaches to Novel Advances
Authors: Irene A. Abela, Lucy Reynell and Alexandra TrkolaTherapeutic antibodies have evolved into an important drug class and have achieved considerable success in combating cancers and autoimmune diseases. Although their potential in the treatment of viral infections has not yet been fully explored, recently established approaches have the potential to aid the development of HIV specific antibody therapies. Antibody engineering has led to improvements in antibody isolation Read More
-
Volumes & issues
-
Volume 31 (2025)
-
Volume 30 (2024)
-
Volume 29 (2023)
-
Volume 28 (2022)
-
Volume 27 (2021)
-
Volume 26 (2020)
-
Volume 25 (2019)
-
Volume 24 (2018)
-
Volume 23 (2017)
-
Volume 22 (2016)
-
Volume 21 (2015)
-
Volume 20 (2014)
-
Volume 19 (2013)
-
Volume 18 (2012)
-
Volume 17 (2011)
-
Volume 16 (2010)
- Issue 38
- Issue 37
- Issue 36
- Issue 35
- Issue 34
- Issue 33
- Issue 32
- Issue 31
- Issue 30
- Issue 29
- Issue 28
- Issue 27
- Issue 26
- Issue 25
- Issue 24
- Issue 23
- Issue 22
- Issue 21
- Issue 20
- Issue 19
- Issue 18
- Issue 17
- Issue 16
- Issue 15
- Issue 14
- Issue 13
- Issue 12
- Issue 11
- Issue 10
- Issue 9
- Issue 8
- Issue 7
- Issue 6
- Issue 5
- Issue 4
- Issue 3
- Issue 2
- Issue 1
-
Volume 15 (2009)
-
Volume 14 (2008)
-
Volume 13 (2007)
-
Volume 12 (2006)
-
Volume 11 (2005)
-
Volume 10 (2004)
-
Volume 9 (2003)
-
Volume 8 (2002)
-
Volume 7 (2001)
-
Volume 6 (2000)
Most Read This Month
Article
content/journals/cpd
Journal
10
5
false
en
